影响使用高生物利用度口服抗生素疗法治疗人工关节感染的因素。
Factors influencing the use of highly bioavailable oral antibiotic therapy for the treatment of prosthetic joint infections.
作者信息
Granger Marie-Félixe, Leis Jerome A, Hempel Amanda, Pincus Daniel, Ravi Bheeshma, Daneman Nick, Lam Philip W
机构信息
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
出版信息
Infect Control Hosp Epidemiol. 2024 Oct 10;45(11):1-4. doi: 10.1017/ice.2024.159.
Abstract
We conducted a retrospective cohort study to identify factors influencing intravenous (IV) versus oral antibiotic therapy in first-episode prosthetic joint infections. Of the 34/78 (44%) cases treated intravenously, negative cultures (26%), concomitant infections necessitating IV antibiotics (21%), and delays in susceptibility testing (15%) were the most common reasons for IV therapy.
摘要
我们进行了一项回顾性队列研究，以确定影响首次人工关节感染时静脉注射与口服抗生素治疗的因素。在34例（占78例中的44%）接受静脉注射治疗的病例中，培养结果为阴性（26%）、伴有需要静脉注射抗生素的感染（21%）以及药敏试验延迟（15%）是静脉注射治疗最常见的原因。
相似文献
1
Factors influencing the use of highly bioavailable oral antibiotic therapy for the treatment of prosthetic joint infections.
Infect Control Hosp Epidemiol. 2024 Oct 10;45(11):1-4. doi: 10.1017/ice.2024.159.
2
Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT.
Health Technol Assess. 2019 Aug;23(38):1-92. doi: 10.3310/hta23380.
3
Effectiveness of early switching from intravenous to oral antibiotic therapy in Staphylococcus aureus prosthetic bone and joint or orthopedic metalware-associated infections.
BMC Musculoskelet Disord. 2021 Mar 30;22(1):315. doi: 10.1186/s12891-021-04191-y.
4
Excellent Outcomes With the Selective Use of Oral Antibiotic Therapy for Bone and Joint Infections: A Single-Center Experience.
Cureus. 2022 Jul 18;14(7):e26982. doi: 10.7759/cureus.26982. eCollection 2022 Jul.
5
Comparison of intravenous and oral definitive antibiotic regimens in hospitalised patients with Gram-negative bacteraemia from a urinary tract infection.
J Glob Antimicrob Resist. 2019 Sep;18:243-248. doi: 10.1016/j.jgar.2019.03.013. Epub 2019 Mar 26.
6
Evaluation of step-down oral antibiotic therapy for uncomplicated streptococcal bloodstream infections on clinical outcomes.
Ther Adv Infect Dis. 2022 Jan 30;9:20499361211073248. doi: 10.1177/20499361211073248. eCollection 2022 Jan-Dec.
7
Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
Pediatrics. 2004 Oct;114(4):e469-76. doi: 10.1542/peds.2004-0421.
8
Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream Infections.
JAMA Netw Open. 2024 Jan 2;7(1):e2349864. doi: 10.1001/jamanetworkopen.2023.49864.
9
Evaluation of Opportunities for Oral Antibiotic Therapy in Bone and Joint Infections.
Ann Pharmacother. 2023 Feb;57(2):156-162. doi: 10.1177/10600280221101105. Epub 2022 Jun 3.
10
Can metagenomic next-generation sequencing identify the pathogens responsible for culture-negative prosthetic joint infection?
BMC Infect Dis. 2020 Mar 30;20(1):253. doi: 10.1186/s12879-020-04955-2.
引用本文的文献
1
Trends in Oral Antibiotic Treatment in Patients Hospitalized with Diabetic Foot Osteomyelitis: A Single-Centre Experience.
J Assoc Med Microbiol Infect Dis Can. 2025 May 29;10(2):179-185. doi: 10.3138/jammi-2024-0042. eCollection 2025 Jun.
本文引用的文献
1
Variation in North American Infectious Disease Specialists' Practice Regarding Oral and Suppressive Antibiotics for Adult Osteoarticular Infections: Results of an Emerging Infections Network (EIN) Survey.
Open Forum Infect Dis. 2024 May 15;11(6):ofae280. doi: 10.1093/ofid/ofae280. eCollection 2024 Jun.
2
Early switch from intravenous to oral antibiotic treatment in bone and joint infections.
Clin Microbiol Infect. 2023 Sep;29(9):1133-1138. doi: 10.1016/j.cmi.2023.05.008. Epub 2023 May 12.
3
Partial-Oral Antibiotic Therapy for Bone and Joint Infections in People With Recent Injection Drug Use.
Open Forum Infect Dis. 2023 Jan 7;10(1):ofad005. doi: 10.1093/ofid/ofad005. eCollection 2023 Jan.
4
Excellent Outcomes With the Selective Use of Oral Antibiotic Therapy for Bone and Joint Infections: A Single-Center Experience.
Cureus. 2022 Jul 18;14(7):e26982. doi: 10.7759/cureus.26982. eCollection 2022 Jul.
5
Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome ranking (DOOR) endpoint.
Int J Antimicrob Agents. 2022 Jul;60(1):106598. doi: 10.1016/j.ijantimicag.2022.106598. Epub 2022 May 6.
6
Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review.
Am J Med. 2022 Mar;135(3):369-379.e1. doi: 10.1016/j.amjmed.2021.10.007. Epub 2021 Oct 27.
7
Clinical Experience of Implementing Oral Versus Intravenous Antibiotics (OVIVA) in a Specialist Orthopedic Hospital.
Clin Infect Dis. 2021 Nov 2;73(9):e2582-e2588. doi: 10.1093/cid/ciaa985.
8
Oral versus Intravenous Antibiotics for Bone and Joint Infection.
N Engl J Med. 2019 Jan 31;380(5):425-436. doi: 10.1056/NEJMoa1710926.
9
Predictors of Peripherally Inserted Central Catheter Occlusion in the Outpatient Parenteral Antimicrobial Therapy Setting.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00900-18. Print 2018 Sep.
10
Demonstration of the weighted-incidence syndromic combination antibiogram: an empiric prescribing decision aid.
Infect Control Hosp Epidemiol. 2012 Apr;33(4):381-8. doi: 10.1086/664768.
Zotero 插件